DiCello Levitt and Eight Other Firms Appointed To Lead Ozempic Multidistrict Litigation

Apr 26, 2024

DiCello Levitt, along with eight other law firms, was appointed to the Plaintiffs’ Leadership Committee this week in the multidistrict litigation against drug makers Novo Nordisk and Eli Lilly, pursuing damages arising from the severe health risks allegedly caused by Ozempic and similar drugs. Judge Gene E.K. Pratter of the United States District Court for the Eastern District of Pennsylvania named Diandra “Fu” Debrosse, Managing Partner of DiCello Levitt’s Birmingham office and Co-Chair of the firm’s Mass Tort division, as a member of the Plaintiffs’ Leadership Committee in this multidistrict litigation affecting thousands of people nationwide.

In this major product liability litigation, patients allege that the drugs Ozempic, Wegovy, and Rybelsus, all manufactured by Novo Nordisk, as well as Eli Lilly’s drugs Mounjaro and Trulicity, cause severe side effects, including intestinal obstruction, gastroparesis, and other acute gastrointestinal injuries.

“Eli Lilly and Novo Nordisk knew about the severe health risks of their drugs commonly advertised as weight-loss and diabetes remedies yet failed to warn patients about the acute dangers of their medication – all to enrich themselves on the backs of thousands of patients who ended up suffering severe health and gastrointestinal problems,” Diandra “Fu” Debrosse said.

DiCello Levitt is joined on the Plaintiffs’ Leadership Committee by Alex Walsh Law, Dilworth Paxson LLP, Fine Kaplan & Black RPC, Johnson Becker PLLC, Levin Papantonio, Morgan & Morgan, Motley Rice LLC, and Susan Law Group.

Comments are closed.